Metabolic switches, such as cancer cells using oxidative phosphorylation, are common themes in persister cell populations resistant to therapy.

“When we look at what drives resistance to both targeted therapy so those molecules I referred to before these surface receptor and downstream molecules that have been successful and extend people's — lives with cancer and immunotherapy and we and we look at common themes in terms of instance this metabolic switch like using oxidative phosphorylation when they weren't using it before like that's a very common theme in what we call the persister cell population — in both therapy types”